Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
The closing price of Rocket Pharmaceuticals Inc (NASDAQ: RCKT) was $2.93 for the day, down -4.56% from the previous closing price of $3.07. In other words, the price has decreased by -$4.56 from its previous closing price. On the day, 3.1 million shares were traded.
Ratios:
Our analysis of RCKT’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 9.19 and its Current Ratio is at 9.19. In the meantime, Its Debt-to-Equity ratio is 0.06 whereas as Long-Term Debt/Eq ratio is at 0.05.
On May 28, 2025, Morgan Stanley Downgraded its rating to Equal-Weight which previously was Overweight but kept the price unchanged to $7.
Leerink Partners Downgraded its Outperform to Market Perform on May 28, 2025, while the target price for the stock was maintained at $8.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on May 20 ’25 when Militello John sold 357 shares for $6.45 per share. The transaction valued at 2,301 led to the insider holds 64,027 shares of the business.
Schwartz Jonathan David sold 801 shares of RCKT for $5,163 on May 20 ’25. The insider now owns 235,255 shares after completing the transaction at $6.45 per share. On May 20 ’25, another insider, Patel Kinnari, who serves as the insider of the company, sold 767 shares for $6.45 each. As a result, the insider received 4,944 and left with 441,927 shares of the company.
Stock Price History:
Over the past 52 weeks, RCKT has reached a high of $26.98, while it has fallen to a 52-week low of $2.19. The 50-Day Moving Average of the stock is -46.77%, while the 200-Day Moving Average is calculated to be -74.56%.
Shares Statistics:
A total of 106.75M shares are outstanding, with a floating share count of 99.77M. Insiders hold about 7.39% of the company’s shares, while institutions hold 87.14% stake in the company.
Earnings Estimates
The market rating of Rocket Pharmaceuticals Inc (RCKT) is currently shaped by the ongoing analysis conducted by 17.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is -$0.53, with high estimates of -$0.15 and low estimates of -$0.66.
Analysts are recommending an EPS of between -$0.9 and -$2.58 for the fiscal current year, implying an average EPS of -$2.12. EPS for the following year is -$1.45, with 17.0 analysts recommending between $0.38 and -$2.31.
